TEAM

Management

Edward M. Kaye, M.D. — Chief Executive Officer

Edward M. Kaye, M.D.

Chief Executive Officer

Ed Kaye is the Chief Executive Officer and a Director of Stoke Therapeutics. Ed served as President and Chief Executive Officer of Sarepta Therapeutics (NASDAQ: SRPT) from September 2016 to June 2017, interim Chief Executive Officer from March 2015 to September 2016, and Chief Medical Officer from June 2011 to April 2017. He also served on the Company’s Board of Directors. Previously, Ed was Group Vice President of Clinical Development at Genzyme Corporation from April 2007 to June 2011, where he supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Ed currently serves as a member of the Boards of Directors of Cytokinetics, Inc., The Massachusetts Biotechnology Council and Neurovia.

Prior to entering the biotech industry, Ed trained in Pediatrics, Pediatric Neurology, and Biochemical Genetics. He was on the research staff of the Massachusetts General Hospital, Tufts University Medical Center and was the Chief of Biochemical Genetics at the Children’s Hospital of Philadelphia. He continues on staff in Pediatric Neurology at the Boston Children’s Hospital. Ed earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine.

Huw M. Nash, Ph.D. — Chief Operating Officer and Chief Business Officer

Huw M. Nash, Ph.D.

Chief Operating Officer and Chief Business Officer

Huw Nash is the Chief Operating Officer and Chief Business Officer of Stoke Therapeutics, and previously was the founding Chief Executive Officer. An Entrepreneur-in-Residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing start-up biotechnology companies. Prior to Stoke, Huw was a co-founder and Vice President of Corporate Development for Aileron Therapeutics (NASDAQ: ALRN). He was also a founding scientist of NeoGenesis Pharmaceuticals, where he served as Vice President of External Collaborations prior to the company’s acquisition by Schering-Plough. Huw received his B.A. in Biochemical Sciences from Harvard College and received his Ph.D. in Organic Chemistry from Harvard University.

Barry Ticho, M.D., Ph.D., FACC — Chief Medical Officer

Barry Ticho, M.D., Ph.D., FACC

Chief Medical Officer

Barry Ticho is the Chief Medical Officer at Stoke Therapeutics, where he is helping to lead the company’s efforts to develop first-in-class therapeutics to treat rare diseases. Prior to joining Stoke, Barry was Head of Development of mRNA treatments for Cardiovascular and Metabolic Diseases at Moderna Therapeutics. Previously, he was Head of External R&D Innovation for Cardiovascular and Metabolic Diseases at Pfizer, and prior to that he was Vice President of Clinical Development at Biogen. Barry obtained his M.D. and Ph.D. degrees from the University of Chicago and completed pediatrics training at Northwestern University and a cardiology fellowship at Children’s Hospital in Boston. He was on clinical staff at Harvard Medical School and Massachusetts General Hospital and conducted laboratory research on the regulation of cardiac development.

Gene Liau, Ph.D. — EVP, Head of Research & Preclinical Development

Gene Liau, Ph.D.

EVP, Head of Research & Preclinical Development

Gene Liau is the Executive Vice President; Head, Research and Preclinical Development at Stoke Therapeutics.  Gene previously served as Senior Vice President and Head of Gene Therapy R&D at Precision BioSciences from 2015-2017. From 2011-2015 he was at Pfizer where, as Executive Director, he led External R&D efforts for Rare Disease and Hematology and spearheaded the Pfizer Gene Therapy initiative.  Prior to Pfizer, he helped Shire build an innovative rare disease portfolio. Gene was at Novartis for twelve years, initially building a Research Unit focused on using gene therapy for cardiovascular and metabolic applications and eventually leading the cardiovascular/metabolic division at the Novartis Institutes for BioMedical Research in Cambridge where he was responsible for projects from target discovery to early clinical PoC. Prior to entering industry, Gene was a Professor at George Washington University Medical Center and also a Senior Scientist at the Jerome H. Holland Laboratory of the American Red Cross.  Gene received his Ph.D. in Biochemistry from Vanderbilt University and did his Postdoctoral Fellowship at the National Cancer Institute.

Isabel Aznarez, Ph.D. — Co-Founder and Vice President, Head of Biology

Isabel Aznarez, Ph.D.

Co-Founder and Vice President, Head of Biology

Isabel Aznarez is a co-founder and Vice President of Biology of Stoke Therapeutics. Isabel has extensive experience in human genetics, RNA metabolism, and modulation of RNA processes using antisense oligonucleotides. Prior to founding Stoke Therapeutics, she was a Research Investigator with Prof. Adrian Krainer, whose lab she joined as a postdoctoral fellow in 2008. Previously, Isabel was a researcher at the Hospital for Sick Children with Prof. Lap-Chee Tsui, where she focused on the effect of cystic fibrosis mutations on the splicing of the CFTR gene. Isabel holds a Ph.D. in Medical & Molecular Genetics from the University of Toronto (2006), and a B.Sc. in Biology and Human Genetics from the University of Uruguay.

Charles R. Allerson, Ph.D. — Vice President of Chemistry

Charles R. Allerson, Ph.D.

Vice President of Chemistry

Chuck Allerson is the Vice President of Chemistry for Stoke Therapeutics. A career nucleoside/oligonucleotide chemist, Chuck has over 15 years’ experience in the design and development of oligonucleotide therapeutics for antisense, RNAi and microRNA targeting applications. Most recently, Chuck was Director of Chemistry for Regulus Therapeutics, and prior to that held roles of increasing responsibility at Ionis Pharmaceuticals and Variagenics. Chuck holds a Ph.D. in organic chemistry from Harvard University, where he studied with Professor Gregory Verdine, and was a post-doctoral researcher at the National Institutes of Health where he worked with Dr. Tracey A. Rouault, M.D.

Meena, Ph.D. — Vice President of Bioanalytical, DMPK and Biomarker Development

Meena, Ph.D.

Vice President of Bioanalytical, DMPK and Biomarker Development

Meena is the Vice President of Bioanalytical, DMPK and Biomarker Development at Stoke Therapeutics. Meena brings 20 years of experience in nucleic acids therapeutics to Stoke. Prior to joining Stoke, Meena served as Senior Director of Bioanalytical, Pharmacology and Biomarker Development at Wave Life Sciences. In her eight years at Wave (formerly Ontorii) and as its first employee, Meena played a pivotal role in building the company’s stereopure oligonucleotide chemistry platform and helping to guide the clinical entry of three antisense programs. Before joining Wave, Meena worked at Alnylam Pharmaceuticals on siRNA chemistry and targeted siRNA delivery. Meena received her Ph.D. in Chemistry with Dr. K.N. Ganesh at the National Chemical Laboratory in Pune, India and did her post-doctoral research on nucleic acids analogues with Prof. Larry W. McLaughlin at Boston College.

Board of Directors

Edward M. Kaye, M.D. — CEO and Director

Edward M. Kaye, M.D.

CEO and Director

Ed Kaye is the Chief Executive Officer and a Director of Stoke Therapeutics. Ed served as President and Chief Executive Officer of Sarepta Therapeutics (NASDAQ: SRPT) from September 2016 to June 2017, interim Chief Executive Officer from March 2015 to September 2016, and Chief Medical Officer from June 2011 to April 2017. He also served on the Company’s Board of Directors. Previously, Ed was Group Vice President of Clinical Development at Genzyme Corporation from April 2007 to June 2011, where he supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Ed currently serves as a member of the Boards of Directors of Cytokinetics, Inc., The Massachusetts Biotechnology Council and Neurovia.

Prior to entering the biotech industry, Ed trained in Pediatrics, Pediatric Neurology, and Biochemical Genetics. He was on the research staff of the Massachusetts General Hospital, Tufts University Medical Center and was the Chief of Biochemical Genetics at the Children’s Hospital of Philadelphia. He continues on staff in Pediatric Neurology at the Boston Children’s Hospital. Ed earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine.

Adrian Krainer, Ph.D. — Co-founder and Director

Adrian Krainer, Ph.D.

Co-founder and Director

Adrian R. Krainer is a co-founder and Director of Stoke Therapeutics, and is the St. Giles Professor of Molecular Genetics and Program Chair of Cancer and Molecular Biology at Cold Spring Harbor Laboratory. Prof. Krainer’s fundamental and applied research on RNA splicing for over three decades directly led to the invention and development of SPINRAZATM (nusinersen), the first approved therapeutic that corrects a splicing defect, and a life-saving drug for infants with spinal muscular atrophy. He is a member of the American Academy of Arts and Sciences, a Pew Scholar in the Biomedical Sciences, and a recipient of an NIH MERIT award and New York Intellectual Property Law Association’s 2017 inventor-of-the-year award.

Arthur A. Levin, Ph.D. — Director

Arthur A. Levin, Ph.D.

Director

Art Levin is a Director of Stoke Therapeutics and has an unparalleled track record and reputation in the field of nucleic acid-based therapeutics. He currently serves as Executive Vice President, Research and Development at Avidity Biosciences. Previously he held that position at miRagen Therapeutics. Prior to that he held senior drug development roles at Ionis Pharmaceuticals and Santaris Pharma. He has played key roles in the development of numerous of oligonucleotides including the first approved antisense NDAs, and the first microRNA-targeted therapeutic in clinical trials. He has a combined three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Art has published over 60 scientific articles and several of the most cited reviews in the field. He serves as a director of the Oligonucleotide Therapeutics Society and holds several additional scientific organization affiliations and honors. He received a doctorate in toxicology from the University of Rochester, and a bachelor’s degree in biology from Muhlenberg College.

Seth L. Harrison, M.D. — Chairman

Seth L. Harrison, M.D.

Chairman

Seth Harrison is the founder and managing partner of Apple Tree Partners (ATP) and is Chairman of the Board of Directors of Stoke Therapeutics. He has invested in life sciences since 1991. He is also currently Chairman of ATP companies Braeburn Pharmaceuticals, Elstar Therapeutics, Limelight Bio, and Syntimmune, and is a Director of Corvidia Therapeutics.

Seth’s prior investments include: Aileron Therapeutics, ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Tokai Pharmaceuticals, Ultracision, and ViroPharma. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides. Prior to founding ATP in 1999, Seth was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds.

Seth received an A.B. from Princeton University, an M.D. and M.B.A. both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.

Samuel W. Hall, Ph.D. — Director

Samuel W. Hall, Ph.D.

Director

Sam Hall is a principal at Apple Tree Partners (ATP) and is a Director of Stoke Therapeutics. Prior to joining ATP in 2013, Sam was a researcher at the University of Cambridge in the U.K., where his work focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development. Prior to Symphony, he served as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements.

Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.

In addition to Stoke Therapeutics, Sam is on the Board of Directors of Syntimmune, Elstar Therapeutics and Limelight Bio.

Arthur Tzianabos, Ph.D. — Director

Arthur Tzianabos, Ph.D.

Director

Dr. Arthur Tzianabos is the president and CEO of Homology Medicines. At Homology, Dr. Tzianabos leads efforts to develop genetic medicines by leveraging its in vivo gene therapy and nuclease-free gene editing platform for patients with rare genetic diseases. He previously served as president and CSO of OvaScience, where he translated early science into treatments for fertility patients. Dr. Tzianabos also spent nine years at Shire, where he worked on the development and launches of multiple treatments for patients with rare genetic disorders and worked closely with the business development team to build Shire’s product pipeline through investments and acquisitions. Earlier in his career, Dr. Tzianabos was a principal investigator and faculty member at Harvard Medical School for 15 years, reaching the rank of associate professor of medicine and maintaining laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos has published more than 80 scientific papers, reviews, book chapters and patents. He is a member of the board of directors for gene therapy company Akouos and serves on the development board for the University of New Hampshire’s College of Life Sciences and Agriculture. Dr. Tzianabos holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.

OPPORTUNITY

Gene-specific up-regulation is needed for many diseases

  • There are 7,000 orphan genetic diseases with 350,000,000 affected individuals worldwide
  • Most are due to loss/reduction of function of a single gene; many are due to loss of one allele (haploinsufficiencies)
  • ONLY 5% have approved treatments
  • Current treatments manage symptoms with little impact on outcomes & life expectancy

SOLUTION

Antisense up-regulation addresses an unmet drug space

APPROACH

Efficient target validation & hit ID pipeline

  • NextGen RNAseq yields whole transcriptome starting datasets for organs targetable by antisense oligonucleotides in humans & animals
  • Stoke’s bioinformatic engine delivers prioritized database of targetable genes
  • Cross-referencing with genetic disease databases identifies thousands of target gene opportunities for monogenic diseases caused by loss or reduction of function
  • Accelerated target to hit ID phase with focused antisense oligonucleotide arrays yields hits within 4 weeks

TECHNOLOGY

Targeted Augmentation of Nuclear Gene Output (TANGO)

TANGO exploits non-productive splicing events to effect targeted enhancement of gene expression

INTELLECTUAL PROPERTY

Dominant IP estate around technology & targets

  • Exclusively licensed foundational TANGO patents from Cold Spring Harbor Laboratory & University of Southampton
  • Core TANGO claims have been allowed by USPTO
  • Company has also filed patents around top drug targets amenable to up-regulation, providing composition of matter-level protection on these genes

DIFFERENTIATED PIPELINE

NEWS

Stay up to date with the latest news from Stoke Therapeutics.

Press Releases
Stoke Therapeutics to Present Research Supporting Advancement of Dravet Syndrome Program at Annual Meeting of the Oligonucleotide Therapeutics Society
September 27, 2018

Stoke Therapeutics Appoints Biotech Veteran Arthur Tzianabos, Ph.D. to Board of Directors
September 17, 2018

Stoke Therapeutics to Present Research Supporting Its Novel Approach to Oligonucleotide Mediated Gene Up-Regulation at TIDES and ASGCT Conferences
May 8th, 2018

Stoke Therapeutics Expands Leadership Team, Building on Deep Expertise in Oligonucleotide Chemistry and Rare Disease Research and Development
April 17th, 2018

Stoke Therapeutics Presents Early Research on its Novel ASO Pipeline for Severe Genetic Diseases at OPT
March 26th, 2018

Stoke Therapeutics Announces $40 Million Series A Financing to Create Pioneering New Medicines that Restore Gene Expression in Severe Genetic Disease
January 4th, 2018

In the News

Startup seeks answers to insidious form of epilepsy
The Boston Globe
May 16, 2018

Stoking Protein Production
BioCentury
April 5th, 2018

Gene Therapy 2.0: New Startups Aim to Fine-Tune Gene Delivery and Control
Xconomy
January 4th, 2018

Antisense player Stoke Therapeutics picks up $40M series A
Fierce Biotech
January 4th, 2018

Posters and Publications

TANGO – Targeted Augmentation of Nuclear Gene Output  for the Treatment of Genetic Diseases
American Society of Gene and Cell Therapy Annual Meeting
April 29 – May 2, 2018

Conferences and Events
The 14th Annual Meeting of the Oligonucleotide Therapeutics Society
September 30 – October 3, 2018
Seattle, WA

Clinical Biomarkers & World CDx Boston
October 4-5, 2018
Boston, MA

2018 Child Neurology Society Annual Meeting 
October 15-18, 2018
Chicago, IL

American Academy of Ophthalmology (AAO) 2018
October 27-30, 2018
Chicago, IL

American Epilepsy Society (AES) 2018 
November 30-December 4, 2018
New Orleans, LA

CAREERS

 

Stoke is always looking for individuals with a passion to develop precision medicines for inherited diseases.
For more info, please contact – careers@stoketherapeutics.com

 

Vice President, Regulatory Affairs
Stoke Therapeutics is looking for a Vice President of Regulatory Affairs to develop and implement a regulatory strategy working closely with cross-functional teams to summarize scientific data and submission packages to US and regulatory agencies.  This position, which reports to the Chief Medical Officer, requires a candidate with a deep knowledge and understanding of the global regulatory environment and a passion for patients with debilitating neurological diseases.

Responsibilities include:

  • Filing and supervising submission of multiple INDs and determining the strategy for multiple projects.
  • Actively leading the development and implementation of regulatory strategy for specific projects including identifying and assessing regulatory risks and pathways for expedited development and timelines.
  • Serving as the regulatory representative on project teams.
  • Active involvement in writing/review of regulatory submissions.
  • Interfacing with Health authorities.
  • Coordinating all aspects of regulatory submissions.
  • Proactively keeping updated on regulatory requirements and expedited approaches worldwide.
  • Hiring, building, supervising and managing a team of regulatory professionals who will support Stoke’s efforts in multiple therapeutic areas.

Minimum Qualifications:

  • Master’s Degree is required, PharmD, PhD or MD degree is preferred.
  • At least 10 years of experience working in Regulatory Affairs; ideally in the biotech industry. Experience in rare diseases, oligonucletotides or neurology is required.
  • Sound knowledge and experience in Regulatory Affairs and associated requirements, plus pharmaceutical industry experience in clinical trial and drug development work with a record of successful drug development through product approval in the US, EU, Asia.
  • Thorough knowledge of the drug development process including all expedited pathways and orphan drug designations, INDs, CTAs, NDAs and MAAs.
  • Experience in interfacing directly with FDA and other Health authorities.

Skills/Competencies:

  • Deep knowledge and understanding of global regulatory requirements and environment.
  • Demonstrated strategic thinking and implementation in overall drug development.
  • Must be able and willing to work diligently in a high-visibility, fast-paced environment and exhibit passion for patients with debilitating neurological diseases.
  • Must be detail-oriented and possess good analytical and problem-solving skills.
  • Excellent verbal and written communication skills and strong interpersonal skills.
  • Ability to hire, manage and develop Regulatory staff members
  • Results=focused and able to work under pressure and to set and meet deadlines.
  • Adaptable and self-motivated, able to prioritize effectively with strong problem solving and planning abilities.

Primary Location
Cambridge, MA and Bedford, MA

Interested candidates should submit a CV and cover letter via e-mail to careers@stoketherapeutics.com.

Director, R&D Program and Alliance Management
Stoke Therapeutics is looking for a Director, R&D Program and Alliance Management to provide strategic and operational management of program research and development activities in support of one or more drug development teams spanning the transition from discovery to development through to post-approval lifecycle management.  This position will report to the Chief Medical Officer and Head of R&D and will be responsible for developing the program strategy, timing, budget, milestones and identifying program risks to be mitigated. The successful candidate will be responsible for maximizing the success of the company’s partnered activities and will be adept at influencing and negotiating with others and with keen ability to translate strategy into action.

Job Responsibilities

  • Collaborate with the Project Leader and cross-functional teams to define program strategy, develop integrated project plans, align team members on project goals and deliverables, address issues and risks associated with achieving the deliverables and ensure appropriate mitigation and contingency plans are in place.
  • Coordinate all activities associated with achieving Program Team goals and business objectives.
  • Build high-level operational plans for program strategy, including alternative and backup scenarios. Identify all critical path activities, inter-linkages between activities as well as critical decision points.
  • Model scenario plans and help generate presentations to support recommendations to senior leadership.
  • Develop and present program timelines for annual operating plan. Collaborate with finance to support tracking of actuals to budget, communicate deviations.
  • Manage project team meetings, cross-functional communication and ensure alignment with other internal as well as external stakeholders.
  • Key role as primary contact for project team related information.
  • Work with team members to establish and maintain a high performing team and serve as a project advocate within the organization.
  • Communicate project status and issues through generation of key documents (monthly reports, timelines, agendas, minutes, etc.) to ensure accurate project information is available to the broader organization to enable pipeline and milestone decisions.
  • Establish and execute overall alliance governance, processes and protocols with academic partners.

Requirements

  • PhD (preferred) or BS/MS in a scientific discipline with experience in leading drug development teams.
  • 10+ years of experience in the biopharmaceutical industry. A focus in rare diseases, neurology and/or nucleic acid therapies is highly desirable.
  • 5+ years of experience leading multi-disciplinary development teams in the execution of operational plans; ideally across multiple functional areas and various development phases.
  • Deep understanding of drug development strategies, across all critical product development disciplines (nonclinical, clinical, CMC, RA/QA, commercial strategy and development).
  • Experience working on clinical development assets.
  • Experience managing alliances with academic or industry partners.
  • Ability to translate strategy into action; strong influence, negotiation, and presentation skills.
  • Strong proficiency with project management practices, tools, software and methodology.
  • Project management and leadership training is preferred.
  • Requires a flexible work schedule to accommodate program priorities as needed.

Primary Location
US-MA-Bedford

Interested candidates should submit a CV and cover letter via e-mail to careers@stoketherapeutics.com.

Vice President, Head of Clinical Operations
Reporting to the Chief Medical Officer, the Vice President, Head of Clinical Operations is responsible for ensuring that Stoke’s clinical stage programs achieve program objectives within established timeframes and financial investments. The position is responsible for delivering on the clinical development plan from study concept through execution, data collection/analysis and final reporting in compliance with applicable standard operating procedures and regulatory requirements. The VP, Head of Clinical Operations will be a member of the Senior Management Team of the Company. This key leadership role is responsible for providing strategic direction for and operational excellence to Stoke’s clinical stage programs.

Job Responsibilities:

  • Act as senior strategic and operational leader for Clinical Operations providing a strong, clear voice both internally and externally
  • Serve as a key leader in the organization and work across the organization to provide clinical operations insights across the cross-functional teams
  • Build and manage/lead a clinical operations team
  • Direct the execution of clinical plans consistent with development strategy, corporate strategy and overall program objectives
  • Oversee the selection and management of all clinical vendors to ensure successful clinical trial implementation while adhering to FDA, EMEA, GCP, and ICH guidelines
  • Oversee the preparation of clinical documents, including protocols, IBs, clinical study reports, presentation of key clinical findings to internal and external constituents and clinical components of regulatory documents
  • Contribute in an active and ongoing manner to the scientific, clinical and commercial development of current and future products.
  • Ensure scientific and strategic integrity of all biostatistics deliverables
  • Employ innovative trial designs & statistical methodologies in the design of efficient and effective clinical trials while ensuring scientific and strategic integrity of deliverables
  • Oversee clinical operations activities (timelines, resource planning, budget/forecast and deliverables related to clinical development projects)
  • Communicate clinical operations progress and issues to senior management and external parties as needed
  • Develop clinical operations quality systems, including SOP’s, document management, clinical operations personnel training and ensures departmental compliance with SOPs, GCP and regulatory requirements
  • Continue to evaluate new initiatives for the department to operate more efficiently including the development of new SOPs
  • Help build and maintain a highly-functional and efficient clinical operations organization including organizational roadmap, hiring/developing new team members, and shaping the organization’s culture around the world, including the assessment of new opportunities

Basic Requirements:

  • Requires a BA/BS, BSN, or related degree
  • Requires at least 15 years relevant clinical experience, with at least 5 years in clinical operations project management, ideally including rare disease experience
  • Technical expertise in and/or understanding of cross-function clinical trials processes from study start-up through study closure (e.g. clinical operations, data management, safety, biostatistics, medical writing)
  • Experience building and leading a broad team of clinical operations specialists, ideally globally
  • Working, in-depth knowledge of industry standards including ICH guidelines, GCPs and the CFR
  • Strong leadership and management skills, excellent teamwork and collaboration skills
  • Direct knowledge of and experience in dealing with, and maintaining strong alliance relationships with, external alliance partners and vendors

Preferred Requirements:

  • Demonstrated, effective project management skills
  • Ability to assess complex issues and identify creative, practical solutions
  • Demonstrated success in meeting project timelines and budgets
  • Demonstrated success in identifying, negotiating and overseeing outsourced services and vendors
  • Ability to foster effective relationships with vendors, investigators, consultants and colleagues
  • Demonstrated ability to work independently, as well as in a team environment
  • Excellent communication, writing and presentation skills
  • International experience a plus

Interested candidates should submit a CV and cover letter via e-mail to careers@stoketherapeutics.com.

Senior Research Associate, Analytical Chemistry
Stoke is seeking an enthusiastic and highly motivated analytical chemist to join the chemistry group. The successful candidate will be responsible for:

  • Characterization of oligonucleotides using LC-MS.
  • Biophysical characterization of oligonucleotides, including Tm, viscosity, and protein binding.
  • Formulation and distribution of oligonucleotides.
  • Characterization of oligonucleotide formulations, including endotoxin and osmolality measurement.
  • Physical and database management of internal compound inventory.
  • Maintenance of the analytical lab and instrumentation.
  • Will work closely with other members of the chemistry team, and collaborate extensively with discovery and development project teams.

Qualifications & Experience:

  • Bachelors or Masters degree in chemistry or biochemistry with 4+ years of relevant experience.
  • Previous experience with LC-MS and other relevant analytical methodologies
  • Ability to work as a team player in a dynamic environment.
  • Strong organizational and record-keeping skills.
  • Prior experience with oligonucleotides is ideal.

Compensation: Compensation will be highly competitive for the industry and directly commensurate with experience.

Interested candidates should submit a CV and cover letter via e-mail to careers@stoketherapeutics.com.

Senior Scientist, Oligonucleotide Chemistry
Stoke is seeking an enthusiastic and highly motivated oligonucleotide chemist to join the chemistry group. The successful candidate will be responsible for:

  • Establishing internal oligonucleotide synthesis capability, including the set-up of new synthesis and purification equipment.
  • Synthesis and purification of oligonucleotides from milligram to multigram scale.
  • Synthesis of oligonucleotide conjugates and oligonucleotides containing novel chemistries.
  • Sourcing of raw materials and all other reagents needed for oligonucleotide synthesis.
  • Maintenance of all oligonucleotide synthesis and purification equipment.
  • Recruiting and managing personnel to support oligonucleotide synthesis activities.
  • Cross-training of other chemistry personnel in oligonucleotide synthesis and purification methodology.
  • Interacting with external oligonucleotide synthesis CMOs to manage orders, assist with troubleshooting, and facilitate technology transfer as needed.
  • Will collaborate extensively with discovery and development project teams.

Qualifications & Experience:

  • D. degree in chemistry or biochemistry and at least 4 years of experience in oligonucleotide chemistry.
  • Previous experience with ÄKTA Oligopilot and/or MerMade oligonucleotide synthesizer platforms.
  • Previous experience with oligonucleotide conjugates is ideal.
  • Strong organizational and record-keeping skills.
  • Strong presentational skills to be able to communicate to both internal and external audiences.
  • Ability to work as a team player in a dynamic environment.

Compensation: Compensation will be highly competitive for the industry and directly commensurate with experience.

Interested candidates should submit a CV and cover letter via e-mail to careers@stoketherapeutics.com.